Adamax is a research-chemical peptide marketed as a nootropic and described by vendors as a modified analogue of Semax, an ACTH-derived peptide. Its structure is described inconsistently across sources, so even its chemical identity is uncertain. It is not an approved medicine in any jurisdiction.

Is Adamax the same as Semax?

No. Adamax is sold as a modified Semax analogue, but that claim has not been demonstrated for Adamax in any published study, and the proposed structure differs between sources. Semax has its own research literature, and those findings cannot be assumed to apply to a differently modified, poorly characterised compound.

Is there any published research on Adamax?

No peer-reviewed research on Adamax itself could be located, in humans or animals. There are no clinical trials, no pharmacokinetic studies, and no controlled cognitive-outcome data. Claims about focus, mood, or BDNF come from vendor pages and forum reports rather than published science.

There is no evidence base that can answer this. Reported effects are anecdotal, drawn from user forums and vendor marketing, and no controlled study has tested Adamax for any cognitive outcome. Anecdote cannot distinguish a real effect from expectation, and users themselves disagree about what it does.

Is Adamax safe, and what side effects are known?

The safety profile of Adamax is unknown. No adverse-effect profile has been established in humans and nothing is documented in the peer-reviewed literature, which reflects an absence of study rather than a clean record. Because its composition and purity are not established, potential effects and interactions cannot be characterised.

Where can I buy Adamax and compare vendors?

Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Cognitive

Buy Adamax – Vendors, Prices, Testing and Evidence

Buy Adamax

Also known as: Adamax peptide · Semax/ACTH-fragment analogue (vendor description)

Evidence grade D — AnecdotalRisk flag

Short answer

A research-market nootropic peptide marketed as a modified analogue of Semax. There is no peer-reviewed pharmacology on Adamax itself, and even its chemical identity is inconsistently described; claims about it are anecdotal.

Where can you buy Adamax?

Crystal Peptides. The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

What is known?

Adamax is a research-chemical peptide sold as a nootropic and described by vendors as a modified analogue of Semax (itself an ACTH-derived peptide). Its exact structure is not consistently defined across sources, and no peer-reviewed study characterising this specific compound has been published. Regulators have encountered it as an unapproved product in border seizures.

What is not established?

Safety

Regulatory status

Not approved for human use in any jurisdiction. Sold as a 'research chemical.' New Zealand's Medsafe recorded it in border seizures and, in a June 2025 submission, proposed classifying ACTH-analogue nootropic peptides (naming Adamax and Semax) as prescription medicines.

Not medical advice. This educational reference is not diagnosis, treatment, prescribing, dosing or emergency guidance. Consult a qualified professional before making health-related decisions.

Regulatory or safety concern: This substance may be unapproved for human use, affect the hormonal system, or be subject to regulator or anti-doping restrictions. Check the cited evidence and rules in your jurisdiction.

Vendor comparison

Buy Adamax: compare vendors

The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

Vendor	Product	Documentation	Shipping	Checked	Action
Crystal Peptides Code PEPTIDES10 −10% · discount code details Sponsored	Adamax research product	Vendor-supplied data COA stated as available Not independently documented	Europe See the localized country store	Jul 18, 2026	View at vendor

Crystal Peptides

Adamax research product

Code PEPTIDES10 −10% · discount code details

What is it?

Research and evidence

Adamax is a peptide sold on the research-chemical market as a nootropic, described by vendors as a modified analogue of Semax, itself a peptide derived from a fragment of the hormone ACTH. That description is roughly where the certainty ends. The exact structure of Adamax is not consistently defined across sources, the proposed sequence differs from vendor to vendor, and no peer-reviewed study characterising this specific molecule has been published. It is not approved for human use in any jurisdiction and is sold only as a research chemical. peptides.cx catalogues it under Cognitive with an evidence grade of D, the lowest grade on the scale, reflecting an absence of evidence rather than evidence of failure.

There is no peer-reviewed human research on Adamax at all: no clinical trials, no pharmacokinetic studies, no controlled cognitive-outcome data. No peer-reviewed animal studies of Adamax specifically could be located either. Vendor materials claim greater blood-brain-barrier penetration or increased BDNF, but none of that is supported by published data on this compound. Semax does have its own research literature, and much of the enthusiasm around Adamax borrows from it, but findings on one peptide cannot be assumed to transfer to a differently modified and poorly characterised molecule. Everything reported about what Adamax does comes from vendor pages and user forums rather than controlled study.

The safety profile of Adamax is unknown. Because it is unapproved and its composition, purity, and pharmacology are not established, its potential adverse effects and interactions cannot be characterised — nothing is documented in the peer-reviewed literature, which is not the same thing as being safe. Regulators have encountered it as an unapproved product: New Zealand's Medsafe recorded Adamax in border seizures and, in a June 2025 submission, proposed classifying ACTH-analogue nootropic peptides, naming Adamax and Semax, as prescription medicines. This page is an educational reference summarising what is and is not known; it is not medical advice, and it does not provide dosing, protocols, or sourcing guidance.

Evidence grade: D

There is no peer-reviewed human research on Adamax. No clinical trials, pharmacokinetic studies, or controlled cognitive-outcome data exist. Reported effects come from vendor pages and user forums only. No peer-reviewed animal studies of Adamax specifically could be located. Related peptides such as Semax have their own literature, but those findings cannot be assumed to transfer to a differently modified, poorly characterised compound.

Human evidence

Animal and preclinical evidence

No peer-reviewed animal studies of Adamax specifically could be located. Related peptides such as Semax have their own literature, but those findings cannot be assumed to transfer to a differently modified, poorly characterised compound.

Proposed mechanisms

Marketed as a Semax-type/ACTH-fragment analogue, but this has not been demonstrated for Adamax in any published study
Vendor materials claim greater blood-brain-barrier penetration or increased BDNF, none supported by peer-reviewed data on this compound
The proposed structure differs between sources, so even the identity of Adamax is uncertain

Safety concerns and known side effects

No adverse-effect profile has been established in humans; nothing is documented in peer-reviewed literature

Regulatory status

Frequently asked questions about Adamax

What is Adamax?: Adamax is a research-chemical peptide marketed as a nootropic and described by vendors as a modified analogue of Semax, an ACTH-derived peptide. Its structure is described inconsistently across sources, so even its chemical identity is uncertain. It is not an approved medicine in any jurisdiction.
Is Adamax the same as Semax?: No. Adamax is sold as a modified Semax analogue, but that claim has not been demonstrated for Adamax in any published study, and the proposed structure differs between sources. Semax has its own research literature, and those findings cannot be assumed to apply to a differently modified, poorly characterised compound.
Is there any published research on Adamax?: No peer-reviewed research on Adamax itself could be located, in humans or animals. There are no clinical trials, no pharmacokinetic studies, and no controlled cognitive-outcome data. Claims about focus, mood, or BDNF come from vendor pages and forum reports rather than published science.
Does Adamax work?: There is no evidence base that can answer this. Reported effects are anecdotal, drawn from user forums and vendor marketing, and no controlled study has tested Adamax for any cognitive outcome. Anecdote cannot distinguish a real effect from expectation, and users themselves disagree about what it does.
Is Adamax approved or legal?: Adamax is not approved for human use in any jurisdiction and is sold as a research chemical. New Zealand's Medsafe recorded it in border seizures and, in a June 2025 submission, proposed classifying ACTH-analogue nootropic peptides such as Adamax and Semax as prescription medicines. Legal status varies by country.
Is Adamax safe, and what side effects are known?: The safety profile of Adamax is unknown. No adverse-effect profile has been established in humans and nothing is documented in the peer-reviewed literature, which reflects an absence of study rather than a clean record. Because its composition and purity are not established, potential effects and interactions cannot be characterised.
Where can I buy Adamax and compare vendors?: Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Common discussion areas

Discussed on nootropics forums as a longer-acting or 'stronger' alternative to SemaxAnecdotal debate about effects on focus and mood, with little agreementUncertainty about what the product actually contains

Sources

Classification of Unscheduled Peptides — Submission to the Medicines Classification Committee (June 2025) — Medsafe — New Zealand Medicines and Medical Devices Safety Authority

Editorial review and transparency

Written by: peptides.cx Editorial Team
Scientific reviewer: No named medical reviewer is currently assigned
Last editorial review: July 18, 2026
Last vendor check: July 18, 2026
Review method: Source review, claim verification, vendor-data separation and regulatory-context review.
Commercial disclosure and conflicts: Vendor relationships do not determine evidence or safety ratings. No named reviewer conflict is recorded because no named reviewer is assigned.

Editorial policy →Evidence grade →Vendor methodology →

Related on peptides.cx

Library →Vendor quality checklist →Safety →Affiliate code: PEPTIDES10